MeSH D008303 - malignant carcinoid syndrome
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Merck & Co | Interferon alfa-2b | Intron A | 1986-06-04 | |||
| Interferon alfa-2b | IntronA | 2000-03-09 | ||||
| Interferon alfa-2b | Viraferon | 2000-03-09 | ||||
| SERB | Telotristat ethyl | Xermelo | 2017-09-17 | |||
| TerSera Therapeutics | Telotristat etiprate | Xermelo | 2027-12-11 | 2017-02-28 |
Clinical Trials
Historical Success Rate
Phase 1
0%0/0
Phase 2
0%0/0
Phase 3
43%3/7
Approved: 3Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use